Gianluca Morelli
5 Papers
Gianluca Morelli is an academic researcher. The author has contributed to research in topics: Internal medicine & Hematology. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Pb2214: correlation between hemorrhagic events and ipset score in patients with essential thrombocythemia
Luca Tosoni,Umberto Pizzano,Rikard Mullai,Gianluca Morelli,Giulia Battaglia,Chiara Callegari,Maria Elena Zannier,Davide Lazzarotto,Erica Simeone,Carla Filì,Daniel Alzetta,Daniela Damiani,Renato Fanin,Mario Tiribelli +13 more
TL;DR: Treatment cornerstone are low dose aspirin and cytoreductive therapy, whose uses are proportionate to the risk of thrombosis assessed through IPSET score, the mainThrombotic risk stratification tool among ET patients.
1
Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
Luca Tosoni,Gianluca Morelli,Maria Elena Zannier,Davide Lazzarotto,Carla Filì,Erica Simeone,Giulia Battaglia,Chiara Callegari,Matteo Fanin,Daniela Damiani,Renato Fanin,Mario Tiribelli +11 more
TL;DR: Results of the study highlight the validity of IPSET-t score in predicting individual hemorrhagic risk among ET patients, suggesting a possible role of IPSET-t scoring system as a global evaluator for vascular events in ET patients.
1
Correction to: Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
Luca Tosoni,Matteo Liberi,Gianluca Morelli,Maria Elena Zannier,Davide Lazzarotto,Carla Filì,Erica Simeone,Giulia Battaglia,Chiara Callegari,Matteo Fanin,Daniela Damiani,Renato Fanin,Mario Tiribelli +12 more
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response
Luca Tosoni,Dora Fabbro,Umberto Pizzano,Rikard Mullai,Gianluca Morelli,Alessandra Franzoni,Giuseppe Damante,Eleonora Toffoletti,Daniela Damiani,Renato Fanin,Mario Tiribelli +10 more
TL;DR: The case of JAK2-mutated PV occurring in a CML CML at the time of deep molecular response (DMR) achievement is presented, after 20 years of disease and various lines of therapy.
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
Mario Tiribelli,Gianluca Morelli,Massimiliano Bonifacio +2 more
TL;DR: Advances in pharmacotherapy for myelofibrosis have yielded novel drugs and improved treatment options, but long-term data and the need for personalized therapy remain key challenges.